Cell‐ and Tissue‐Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin

다국어 초록 (Multilingual Abstract)

Venetoclax (ABT‐199) and idasanutlin (RG7388) are efficient anticancer drugs targeting two essential apoptosis markers, Bcl‐2 and MDM2, respectively. Recent studies have shown that the combination of these two drugs leads to remarkable enhancement of anticancer efficacy, both in vitro and in vivo. In an attempt to disclose the relationships of their protein targets, competitive affinity‐based proteome profiling coupled with bioimaging was employed to characterize their protein targets in the same cancer cell line and tumor tissue. A series of protein hits, including ITPR1, GSR, RER1, PDIA3, Apoa1, and Tnfrsf17 were simultaneously identified by pull‐down/LC–MS/MS with the two sets of affinity‐based probes. Dual imaging was successfully carried out, with the simultaneous detection of Bcl‐2 and MDM2 expression in various cancer cells. This could facilitate the novel diagnostic and therapeutic strategies of dual targeting of Bcl‐2/MDM2.
Sondierungsversuche: Von den Kombinationswirkstoffen Venetoclax (ABT‐199) und Idasanutlin (RG7388) abgeleitete Sonden (siehe Beispiele) wurden genutzt, um die zellulären und gewebespezifischen Zielproteine mittels „Pull‐down”/LC‐MS/MS zu identifizieren. Duale Bildgebung ermöglichte die gleichzeitige Detektion der Aktivität und Expression von Apoptosemarkern in verschiedenen Krebszellen.